检查虚弱对接受左心室辅助器械治疗的成年人结果的长期影响
The Journal of cardiovascular nursing
|October 25, 2024
概括
左心室辅助装置 (LVAD) 植入可以逆转心力衰竭患者的身体虚弱. 持续的脆弱性改善与更好的长期生活质量和减少抑郁症有关.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 康复医学 康复医学 康复医学
背景情况:
- 在接受左心室辅助器件 (LVAD) 植入的末期心力衰竭患者中,脆弱性很普遍.
- 虽然有证据表明,短暂的虚弱性可逆转变,但长期的结果和与抑郁症,生活质量 (QoL) 和认知相关的关联在六个月以后仍然不清楚.
研究的目的:
- 为了调查从LVAD植入前到植入后12个月的身体虚弱,抑郁,生活质量和认知的变化.
- 确定脆弱性轨迹及其与1年内患者报告的关键结果的关系.
主要方法:
- 来自机构数据库的临床数据和患者报告结果的回顾性分析.
- 在LVAD前,3个月,6个月和植入后12个月评估身体虚弱,抑郁,生活质量和认知能力.
- 统计分析以比较随时间变化并识别脆弱轨迹的变化.
主要成果:
- 在46名参与者中,76%是男性,平均年龄为64.7岁;25人最初是脆弱的.
- 在LVAD后的12个月内,身体脆弱性下降了近50%.
- 在虚弱,抑郁和 QoL (P < .001) 中观察到显著改善;认知改善在统计学上没有显著意义.
- 持久性虚弱的患者在12个月后的抑郁症,生活质量和认知得分比那些不虚弱或变得不虚弱的患者更差.
结论:
- 在一些心力衰竭患者中,左心室辅助装置 (LVAD) 植入可以导致持续的身体脆弱性逆转.
- 未能改善LVAD后的脆弱性与较差的长期患者报告结果有关.
- 未来的研究应该专注于确定对LVAD治疗的身体脆弱反应的预测因素.
更多相关视频
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.5K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.4K
相关概念视频
Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure V: Nursing Interventions
1
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
1
Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
